TY - JOUR
T1 - Prostaglandin D2 and histamine during the immediate and the late-phase components of allergic cutaneous responses
AU - Pienkowski, Marek M.
AU - Adkinson, N. Franklin
AU - Plaut, Marshall
AU - Norman, Philip S.
AU - Lichtenstein, Lawrence M.
N1 - Funding Information:
From The Johns Hopkins University School of Medicine, Division of Clinical Immunology, Baltimore, Md., and the *University of Tennessee,K noxville, Tenn. Supported by National Institutes of Health Grants AI04866, AIO8270, A121073, and AI07056. Received for publication July 13, 1987. Accepted for publication Jan. 20, 1988. Reprint requests:P hilip S. Norman, MD, The JohnsH opkins Uni-versity School of Medicine, Clinical Immunology Division, at the Good Samaritan Hospital, 5601 Loch Raven Blvd., Balti-more, MD 21239. **Recipient of a Pfizer Biomedical ResearchA ward. Publication No. 722 of the O’Neill Research Laboratories, The Good Samaritan Hospital, Baltimore, Md.
PY - 1988/7
Y1 - 1988/7
N2 - With a skin blister technique in which the mediators generated by the trauma of forming the blister are allowed to subside, we have collected human interstitial skin fluid during the course of allergic reactions to ragweed, and measured levels of histamine and prostaglandin D2 (PGD2). Of 18 ragweed-allergic individuals tested, 11 developed both an immediate and a late-phase reaction (LPR) with fivefold-elevated levels of histamine (40 ng/ml) at 30 minutes and a peak level of PGD2 (6.5 ng/ml) later at 2 1 2 hours after ragweed challenge. The other seven allergic individuals had immediate reactions without an LPR lesion and demonstrated somewhat smaller elevations of histamine (25 ng/ml) but much lower levels of PGD2 (1.6 ng/ml; p < 0.05). The time course of appearance of these mediators was identical in both groups of patients. The fluids from unchallenged blisters of allergic and nonallergic patients and the fluids of nonallergic patients challenged with ragweed had similar levels of histamine, at the lower limit of detection, and undetectable PGD2 levels. The peak levels of PGD2 in allergic individuals correlated with the size of the LPR lesion (p < 0.05). These data suggest that the LPR involves the secondary elaboration of mediators different from mediators responsible for the immediate manifestations of the allergic skin reaction.
AB - With a skin blister technique in which the mediators generated by the trauma of forming the blister are allowed to subside, we have collected human interstitial skin fluid during the course of allergic reactions to ragweed, and measured levels of histamine and prostaglandin D2 (PGD2). Of 18 ragweed-allergic individuals tested, 11 developed both an immediate and a late-phase reaction (LPR) with fivefold-elevated levels of histamine (40 ng/ml) at 30 minutes and a peak level of PGD2 (6.5 ng/ml) later at 2 1 2 hours after ragweed challenge. The other seven allergic individuals had immediate reactions without an LPR lesion and demonstrated somewhat smaller elevations of histamine (25 ng/ml) but much lower levels of PGD2 (1.6 ng/ml; p < 0.05). The time course of appearance of these mediators was identical in both groups of patients. The fluids from unchallenged blisters of allergic and nonallergic patients and the fluids of nonallergic patients challenged with ragweed had similar levels of histamine, at the lower limit of detection, and undetectable PGD2 levels. The peak levels of PGD2 in allergic individuals correlated with the size of the LPR lesion (p < 0.05). These data suggest that the LPR involves the secondary elaboration of mediators different from mediators responsible for the immediate manifestations of the allergic skin reaction.
UR - http://www.scopus.com/inward/record.url?scp=0023820372&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023820372&partnerID=8YFLogxK
U2 - 10.1016/0091-6749(88)90057-7
DO - 10.1016/0091-6749(88)90057-7
M3 - Article
C2 - 3292634
AN - SCOPUS:0023820372
SN - 0091-6749
VL - 82
SP - 95
EP - 100
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 1
ER -